Alliance Global analyst Scott Henry raised the firm’s price target on Fortress Biotech (FBIO) to $4.50 from $4 and keeps a Buy rating on the shares following the Q3 report. The company’s operating expenses are lower now in the absence of Checkpoint, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FBIO:
- Fortress Biotech’s Subsidiary Resubmits NDA for CUTX-101
- Journey Medical Corporation Reports Strong Q3 2025 Growth
- Fortress Biotech’s Earnings Call Highlights EMROSI Success
- Fortress Biotech reports Q3 EPS 11c vs (76c) last year
- Fortress subsidiary announces Crystalys dosed patient in study of dotinurad